A Cost-effective Bioreactor to Advance Functional Tissue Engineering of Cartilage

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$595,571.00
Award Year:
2012
Program:
STTR
Phase:
Phase II
Contract:
2R42AR059433-02
Award Id:
n/a
Agency Tracking Number:
R42AR059433
Solicitation Year:
2012
Solicitation Topic Code:
NIAMS
Solicitation Number:
PA11-097
Small Business Information
501 N GRAHAM, SUITE 250, PORTLAND, OR, 97227-1651
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
831184044
Principal Investigator:
MICHAELBOTTLANG
(503) 413-5457
MBOTTLANG@BIOMECHRESEARCH.ORG
Business Contact:
TREVORLUJAN
(503) 413-5487
trevor.lujan@gmail.com
Research Institute:
EMANUEL HOSPITAL AND HEALTH CENTER

EMANUEL HOSPITAL AND HEALTH CENTER
1225 NE 2ND AVENUE
PORTLAND, OR, 97232-
() -

Abstract
DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develo replacement cartilage using tissue engineering (TE) technologies.Although TE cartilage currently lacks the mechanical resilience of native cartilage, the mechanical properties of TE constructs can be enhanced by applying chemical and mechanical stimuli during culture. To speed the discovery of optimal stimulation protocols, research platforms need to be available that enable fast, clear and reliable communication of functional outcomes (i.e. mechanical properties). Towards this goal, we introduce a compact six-station bioreactor that combines the efficiency of batch testing with the accuracy normally reserved for dedicated single-specimen material test systems. In the highly successful phase I feasibility study, an innovative method was proven to deliver accurate dynamic stimulations and evaluate mechanical properties insix stations. This technology can now be incorporated into a multi-axial frame that uses hybrid and adaptive controls to maximize testing efficiency and flexibility. The first three aims of this application are to 1) increase throughput, 2) add loading modalities and 3) automate performance and analysis tools. The effect of these modifications on mechanical accuracy will be verified using external sensors and imaging methods. Hydrogels and bovine cartilage will be tested in the high- throughput bioreactor and a conventional single-station test system to validate the bioreactors automated measurement of mechanical properties. System robustness will be determined by quantifying the effect of operating the bioreactor for millions of cycles. In the fourth aim,bioreactor prototypes will be distributed to three cartilage TE laboratories to evaluate and optimize the bioreactor prior to commercial launch. Successful completion of the study aims will provide an efficient, reliable and flexible research platform to advance the development and clinical transfer of cartilage TE technology. PUBLIC HEALTH RELEVANCE: Tissue engineering of articular cartilage presents a promising strategy for treatment of osteoarthritis, a debilitating and prevalent disease. Cartilage engineering techniques, however, are currently unable to reproduce the mechanical properties critical to native cartilage, thus impeding the transfer of TE technology to patient care. A bioreactor is therefore proposed to facilitate the rapid discovery of mechanical conditions that promote the biosynthesis of mechanically viable tissue.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government